Topical treatment of psoriatic skin with methotrexate cream: a clinical, pharmacokinetic, and histological study
Open Access
- 1 November 1986
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 66 (6) , 515-519
- https://doi.org/10.2340/0001555566515519
Abstract
Five patients were treated with either 0.25% methotrexate cream or placebo in a double blind trial. The evaluation showed no clinical or histological effect although the drug was absorbed from the skin. Methotrexate (MTX) accumulated in locally treated psoriasis plaques as well as in untreated plaques. The psoriatic skin concentrations were increased by a factor of 119 and 4, respectively. This observation is discussed in relation to the possible role of action of methotrexate in psoriasis. We suggest that methotrexate inhibits the chemotaxis of neutrophil leukocytes systemically and not primarily in the skin, thereby preventing development of the early stages in the psoriatic lesions.This publication has 4 references indexed in Scilit:
- NEUTROPHIL AND MONOCYTE CHEMOTAXIS IN METHOTREXATE-TREATED PSORIASIS PATIENTS1985
- Cutaneous Blood Flow in PsoriasisJournal of Investigative Dermatology, 1983
- Dermo-Epidermal Separation with SuctionJournal of Investigative Dermatology, 1967
- Effects of different dose schedules of amethopterin on serum and tissue concentrations and urinary excretion patternsClinical Pharmacology & Therapeutics, 1962